MEDNAX
- Home ›
- US ›
- Healthcare
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. The last earnings update was 68 days ago. More info.
Add to Portfolio Compare Print
- MEDNAX has significant price volatility in the past 3 months.
MD Share Price and Events
7 Day Returns
1 Year Returns
MD Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| MEDNAX (MD) | -4.1% | -11.6% | -29.6% | -50% | -64.5% | -56.7% |
| US Healthcare | -3% | -7.7% | -11.8% | -5.1% | 10.9% | 60.2% |
| US Market | -0.8% | 2.7% | 7.5% | 7% | 37.9% | 47% |
1 Year Return vs Industry and Market
- MD underperformed the Healthcare industry which returned -5.1% over the past year.
- MD underperformed the Market in United States of America which returned 7% over the past year.
Value
Is MEDNAX undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
MEDNAX
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for MEDNAX.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 15 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 9.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Unlevered Beta | Simply Wall St/ S&P Global | 0.71 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.712 (1 + (1- 21%) (89.21%)) |
1.143 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.14 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.143 * 5.96%) |
9.54% |
Discounted Cash Flow Calculation for NYSE:MD using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for MEDNAX is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 9.54%) |
|
|---|---|---|---|
| 2019 | 373.06 | Analyst x7 | 340.56 |
| 2020 | 363.70 | Analyst x6 | 303.09 |
| 2021 | 396.50 | Analyst x2 | 301.64 |
| 2022 | 423.72 | Est @ 6.86% | 294.26 |
| 2023 | 447.54 | Est @ 5.62% | 283.74 |
| 2024 | 468.83 | Est @ 4.76% | 271.34 |
| 2025 | 488.27 | Est @ 4.15% | 257.97 |
| 2026 | 506.45 | Est @ 3.72% | 244.27 |
| 2027 | 523.80 | Est @ 3.42% | 230.62 |
| 2028 | 540.64 | Est @ 3.22% | 217.30 |
| Present value of next 10 years cash flows | $2,744.79 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $540.64 × (1 + 2.73%) ÷ (9.54% – 2.73%) |
$8,152.18 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $8,152.18 ÷ (1 + 9.54%)10 |
$3,276.65 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $2,744.79 + $3,276.65 |
$6,021.44 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $6,021.44 / 86.56 |
$69.57 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $69.57 |
| Current discount | Discount to share price of
$25.57
= -1 x ($25.57 - $69.57) / $69.57 |
63.2% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- MEDNAX's share price is below the future cash flow value, and at a moderate discount (> 20%).
- MEDNAX's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for MEDNAX's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
MEDNAX's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $2.95 |
| NYSE:MD Share Price ** | NYSE (2019-04-22) in USD | $25.57 |
| United States of America Healthcare Industry PE Ratio | Median Figure of 53 Publicly-Listed Healthcare Companies | 20.9x |
| United States of America Market PE Ratio | Median Figure of 3,080 Publicly-Listed Companies | 18.21x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of MEDNAX.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NYSE:MD Share Price ÷ EPS (both in USD) = 25.57 ÷ 2.95 |
8.67x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- MEDNAX is good value based on earnings compared to the US Healthcare industry average.
- MEDNAX is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does
MEDNAX's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 8.67x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts |
-1.6%per year |
| United States of America Healthcare Industry PEG Ratio | Median Figure of 40 Publicly-Listed Healthcare Companies | 1.48x |
| United States of America Market PEG Ratio | Median Figure of 2,109 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 8.67x ÷ -1.6% |
-5.33x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- MEDNAX earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
MEDNAX's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $35.69 |
| NYSE:MD Share Price * | NYSE (2019-04-22) in USD | $25.57 |
| United States of America Healthcare Industry PB Ratio | Median Figure of 92 Publicly-Listed Healthcare Companies | 2.33x |
| United States of America Market PB Ratio | Median Figure of 5,186 Publicly-Listed Companies | 1.91x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NYSE:MD Share Price ÷ Book Value per Share (both in USD) = 25.57 ÷ 35.69 |
0.72x |
* Primary Listing of MEDNAX.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- MEDNAX is good value based on assets compared to the US Healthcare industry average.
Value checks
We assess MEDNAX's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check) MEDNAX has a total score of 5/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is MEDNAX expected to perform in the next 1 to 3 years based on estimates from 15 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- MEDNAX's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
- MEDNAX's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
- MEDNAX's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NYSE:MD Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts | -1.6% |
| NYSE:MD Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts | 3.4% |
| United States of America Healthcare Industry Earnings Growth Rate | Market Cap Weighted Average | 13.2% |
| United States of America Healthcare Industry Revenue Growth Rate | Market Cap Weighted Average | 7.1% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.5% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 4,035 | 419 | 249 | 5 |
| 2020-12-31 | 3,889 | 391 | 260 | 15 |
| 2019-12-31 | 3,729 | 364 | 236 | 15 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 3,647 | 290 | 269 |
| 2018-09-30 | 3,625 | 358 | 345 |
| 2018-06-30 | 3,598 | 417 | 345 |
| 2018-03-31 | 3,525 | 420 | 329 |
| 2017-12-31 | 3,458 | 511 | 320 |
| 2017-09-30 | 3,378 | 447 | 262 |
| 2017-06-30 | 3,337 | 443 | 293 |
| 2017-03-31 | 3,266 | 455 | 312 |
| 2016-12-31 | 3,183 | 444 | 325 |
| 2016-09-30 | 3,094 | 417 | 340 |
| 2016-06-30 | 2,988 | 393 | 334 |
| 2016-03-31 | 2,893 | 389 | 336 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
All data from MEDNAX Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 3.19 | 3.63 | 2.61 | 4.00 |
| 2020-12-31 | 3.04 | 3.80 | 2.63 | 13.00 |
| 2019-12-31 | 2.71 | 2.89 | 2.51 | 13.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | 2.95 |
| 2018-09-30 | 3.73 |
| 2018-06-30 | 3.72 |
| 2018-03-31 | 3.56 |
| 2017-12-31 | 3.47 |
| 2017-09-30 | 2.84 |
| 2017-06-30 | 3.17 |
| 2017-03-31 | 3.37 |
| 2016-12-31 | 3.52 |
| 2016-09-30 | 3.67 |
| 2016-06-30 | 3.61 |
| 2016-03-31 | 3.62 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess MEDNAX's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
MEDNAX has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has MEDNAX performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- MEDNAX's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
- MEDNAX's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- MEDNAX's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.
Earnings and Revenue History
All data from MEDNAX Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 3,647.12 | 268.63 | 475.28 | |
| 2018-09-30 | 3,625.25 | 344.52 | 471.08 | |
| 2018-06-30 | 3,597.55 | 344.82 | 469.61 | |
| 2018-03-31 | 3,524.57 | 329.11 | 464.72 | |
| 2017-12-31 | 3,458.31 | 320.37 | 459.71 | |
| 2017-09-30 | 3,378.26 | 262.35 | 443.26 | |
| 2017-06-30 | 3,337.32 | 292.98 | 435.29 | |
| 2017-03-31 | 3,266.13 | 311.71 | 424.39 | |
| 2016-12-31 | 3,183.16 | 324.91 | 410.57 | |
| 2016-09-30 | 3,094.13 | 339.54 | 392.52 | |
| 2016-06-30 | 2,988.40 | 333.81 | 379.24 | |
| 2016-03-31 | 2,893.23 | 335.51 | 359.53 | |
| 2015-12-31 | 2,780.00 | 336.32 | 337.52 | |
| 2015-09-30 | 2,688.78 | 332.02 | 315.96 | |
| 2015-06-30 | 2,593.01 | 327.44 | 296.42 | |
| 2015-03-31 | 2,511.97 | 322.33 | 284.85 | |
| 2014-12-31 | 2,438.91 | 317.28 | 275.33 | |
| 2014-09-30 | 2,355.78 | 307.86 | 261.92 | |
| 2014-06-30 | 2,284.00 | 298.61 | 255.93 | |
| 2014-03-31 | 2,217.64 | 288.81 | 249.71 | |
| 2013-12-31 | 2,154.01 | 280.52 | 244.61 | |
| 2013-09-30 | 2,057.96 | 267.65 | 236.74 | |
| 2013-06-30 | 1,976.36 | 256.60 | 230.29 | |
| 2013-03-31 | 1,896.71 | 247.92 | 223.89 | |
| 2012-12-31 | 1,816.61 | 240.91 | 217.44 | |
| 2012-09-30 | 1,750.18 | 233.16 | 206.92 | |
| 2012-06-30 | 1,684.71 | 225.49 | 201.73 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- MEDNAX has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- MEDNAX used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.
- MEDNAX's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess MEDNAX's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
MEDNAX has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is MEDNAX's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up MEDNAX's finances.
The net worth of a company is the difference between its assets and liabilities.
- MEDNAX is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- MEDNAX's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from MEDNAX Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 3,087.88 | 1,974.53 | 58.67 |
| 2018-09-30 | 3,015.31 | 2,006.49 | 48.43 |
| 2018-06-30 | 3,186.92 | 1,891.97 | 47.96 |
| 2018-03-31 | 3,143.49 | 1,966.40 | 51.78 |
| 2017-12-31 | 3,066.45 | 1,852.82 | 70.49 |
| 2017-09-30 | 2,916.57 | 1,826.46 | 59.38 |
| 2017-06-30 | 2,838.25 | 1,773.17 | 51.58 |
| 2017-03-31 | 2,762.47 | 1,902.35 | 52.98 |
| 2016-12-31 | 2,760.77 | 1,705.68 | 66.98 |
| 2016-09-30 | 2,667.34 | 1,788.80 | 63.29 |
| 2016-06-30 | 2,558.05 | 1,439.45 | 62.48 |
| 2016-03-31 | 2,460.60 | 1,442.70 | 64.28 |
| 2015-12-31 | 2,437.85 | 1,274.70 | 60.43 |
| 2015-09-30 | 2,333.74 | 1,362.29 | 68.94 |
| 2015-06-30 | 2,220.30 | 1,296.90 | 70.43 |
| 2015-03-31 | 2,114.06 | 897.16 | 56.99 |
| 2014-12-31 | 2,265.57 | 568.77 | 53.96 |
| 2014-09-30 | 2,505.11 | 288.50 | 79.10 |
| 2014-06-30 | 2,404.78 | 178.69 | 25.28 |
| 2014-03-31 | 2,307.08 | 248.21 | 27.50 |
| 2013-12-31 | 2,342.99 | 27.24 | 37.59 |
| 2013-09-30 | 2,234.09 | 123.76 | 21.16 |
| 2013-06-30 | 2,193.15 | 154.08 | 20.17 |
| 2013-03-31 | 2,105.76 | 184.30 | 39.96 |
| 2012-12-31 | 2,035.37 | 144.33 | 27.86 |
| 2012-09-30 | 1,949.11 | 48.35 | 71.89 |
| 2012-06-30 | 1,870.11 | 0.38 | 15.46 |
- MEDNAX's level of debt (63.9%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (1.3% vs 63.9% today).
- Debt is not well covered by operating cash flow (14.7%, less than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 5.3x coverage).
Financial health checks
We assess MEDNAX's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) MEDNAX has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is MEDNAX's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
MEDNAX
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate MEDNAX's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate MEDNAX's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
| United States of America Healthcare Industry Average Dividend Yield | Market Cap Weighted Average of 21 Stocks | 1.6% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2008 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-12-31 | 0.00 | 3.00 |
| 2020-12-31 | 0.00 | 4.00 |
| 2019-12-31 | 0.00 | 4.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as MEDNAX has not reported any payouts.
- Unable to verify if MEDNAX's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess MEDNAX's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can MEDNAX afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) MEDNAX has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $9,938,017 |
| AGE | 71 |
| TENURE AS CEO | 16.1 years |
CEO Bio
Dr. Roger J. Medel, M.D., Co-Founded at MEDNAX, Inc. (also known as Pediatrix Medical Group Inc.) in 1979. Dr. Medel served as the MEDNAX, Inc.’s President until May 2000 and as Chief Executive Officer until December 2002. In March 2003, Dr. Medel reassumed the position of President, serving in that position until May 2004, and Chief Executive Officer, a position in which he continues to serve today. Dr. Medel served as the Chairman of MEDNAX, Inc. He has been a Director of MEDNAX, Inc. since 1979. Dr. Medel has served as a member of the Board of Trustees of the Dana Farber Cancer Institute, Inc. since January 2016. Dr. Medel has been an Instructor in Pediatrics at the University of Miami. Dr. Medel was a member of the Board of Trustees of the University of Miami from January 2004 to February 2012. He is employed at MBF Healthcare Partners, L.P. He also serves as a Member of the Board of Directors of Simply Healthcare Plans, Care Plus Inc. and previously was a Member of the Board of Directors of Sechrist Industries Inc., MBF Healthcare Acquisition Corp., CarePlus Health Plans, Inc., Sechrist Industries Inc., and ARC Broward Inc. He holds an M.D. He also holds a Masters Degree in Business Administration from the University of Miami.
CEO Compensation
- Roger's compensation has increased by more than 20% in the past year.
- Roger's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the MEDNAX management team in years:
- The tenure for the MEDNAX management team is about average.
Management Team
Roger Medel
Co-Founder
$10M
71
16.1 yrs
Joe Calabro
President
$6M
57
14.9 yrs
Steve Farber
Executive VP & CFO
$6M
48
0.4 yrs
David Clark
Chief Operating Officer
$4M
51
0.2 yrs
Dominic Andreano
Senior VP
$2M
49
6.9 yrs
John Pepia
Senior VP & Chief Accounting Officer
55
2.9 yrs
Tony Ambegaoker
Corporate Chief Information Officer
2.3 yrs
Charles Lynch
Vice President of Strategy & Investor Relations
Mary Ann Moore
Chief Compliance Officer
0.3 yrs
James Swift
Chief Development Officer
5.3 yrs
Board of Directors Tenure
Average tenure and age of the MEDNAX board of directors in years:
- The average tenure for the MEDNAX board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Cesar Alvarez
Chairman of the Board
$250K
70
14.9 yrs
Roger Medel
Co-Founder
$10M
71
40.3 yrs
Waldemar Carlo
Director
$210K
65
19.8 yrs
Paul Gabos
Director
$220K
52
16.4 yrs
Manuel Kadre
Lead Independent Director
$235K
52
5.1 yrs
Mike Fernandez
Director
$200K
65
23.5 yrs
Enrique Sosa
Director
$200K
78
14.9 yrs
Pascal Goldschmidt
Director
$210K
63
13.1 yrs
Karey Barker
Director
$200K
50
3.9 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15. Mar 19 | Sell | Pascal Goldschmidt | Individual | 13. Mar 19 | 13. Mar 19 | -3,300 | $30.40 | $-100,331 | ||
| 20. Sep 18 | Sell | Elliott Management Corporation | Company | 02. Aug 18 | 20. Sep 18 | -859,000 | $48.57 | $-40,630,809 | ||
| 13. Jun 18 | Sell | John Pepia | Individual | 12. Jun 18 | 12. Jun 18 | -6,516 | $46.56 | $-303,374 | ||
| 13. Jun 18 | Sell | Vivian Lopez-Blanco | Individual | 12. Jun 18 | 12. Jun 18 | -13,942 | $46.46 | $-647,775 | ||
| 13. Jun 18 | Sell | Dominic Andreano | Individual | 11. Jun 18 | 11. Jun 18 | -18,000 | $46.95 | $-845,059 | ||
| 01. Jun 18 | Sell | Joseph Calabro | Individual | 01. Jun 18 | 01. Jun 18 | -22,186 | $45.20 | $-1,002,738 | ||
Management checks
We assess MEDNAX's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) MEDNAX has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
The MEDNAX (NYSE:MD) Share Price Is Down 60% So Some Shareholders Are Wishing They Sold
So they might be feeling emotional about the 60% share price collapse, in that time. … Shareholders have had an even rougher run lately, with the share price down 24% in the last 90 days. … While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance.
Simply Wall St - – Full articleRead This Before You Buy MEDNAX, Inc. (NYSE:MD) Because Of Its P/E Ratio
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … To keep it practical, we'll show how MEDNAX, Inc.'s (NYSE:MD) P/E ratio could help you assess the value on offer. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleAre Insiders Selling MEDNAX, Inc. (NYSE:MD) Stock?
So shareholders might well want to know whether insiders have been buying or selling shares in MEDNAX, Inc. … The Last 12 Months Of Insider Transactions At MEDNAX. … Over the last year we saw more insider selling of MEDNAX shares, than buying
Simply Wall St - – Full articleIs MEDNAX, Inc. (NYSE:MD) A Financially Sound Company?
Today we will look at MD’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis. … MD’s Debt (And Cash Flows)
Simply Wall St - – Full articleWhat Do Analysts Think About MEDNAX, Inc.'s (NYSE:MD) Growth?
(NYSE:MD) released its latest earnings announcement on 31 December 2018, … with earnings expected to decline by -12% in the upcoming year
Simply Wall St - – Full articleWhat Should We Expect From MEDNAX, Inc.'s (NYSE:MD) Earnings Over The Next Few Years?
Want to participate in a short research study? … Help shape the future of investing tools and you could win a $250 gift card! … (NYSE:MD) announced its most recent earnings update, which
Simply Wall St - – Full articleWhy MEDNAX, Inc.’s (NYSE:MD) Return On Capital Employed Looks Uninspiring
In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … Return On Capital Employed (ROCE): What is it? … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.
Simply Wall St - – Full articleInvestors Are Undervaluing MEDNAX, Inc. (NYSE:MD) By 43.37%
by taking the expected future cash flows and discounting them to their present value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleMEDNAX, Inc. (NYSE:MD): Exploring Free Cash Flows
What is left after investment, determines the value of the stock since this cash flow technically belongs to investors of the company. … MEDNAX generates cash through its day-to-day business, which needs to be reinvested into the company in order for it to continue operating. … I will be analysing MEDNAX’s FCF by looking at its FCF yield and its operating cash flow growth.
Simply Wall St - – Full articleIs MEDNAX, Inc.'s (NYSE:MD) CEO Overpaid Relative To Its Peers?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Roger Medel's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$2.9b, and pays its CEO total annual compensation worth US$7.4m.
Simply Wall St - – Full articleCompany Info
Description
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and their unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of December 31, 2018, it had a network of approximately 4,210 affiliated physicians. The company was founded in 1979 and is based in Sunrise, Florida.
Details
| Name: | MEDNAX, Inc. |
| MD | |
| Exchange: | NYSE |
| Founded: | 1979 |
| $2,213,291,511 | |
| 86,558,135 | |
| Website: | http://www.mednax.com |
| Address: |
MEDNAX, Inc. 1301 Concord Terrace, Sunrise, Florida, 33323, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NYSE | MD | Common Stock | New York Stock Exchange | US | USD | 20. Sep 1995 | |
| DB | PDC | Common Stock | Deutsche Boerse AG | DE | EUR | 20. Sep 1995 | |
| BMV | MD * | Common Stock | Bolsa Mexicana de Valores | MX | MXN | 20. Sep 1995 |
Number of employees
Current staff
Industry
| Health Care Services | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/23 00:22 |
| End of day share price update: | 2019/04/22 00:00 |
| Last estimates confirmation: | 2019/04/17 |
| Last earnings filing: | 2019/02/14 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
